September 26th- Live from IMS 2026: Take-Home Message and Summary of IMS 2026

CME Congresses .

September 26th- Live from IMS 2026: Take-Home Message and Summary of IMS 2026

September 26th- Live from IMS 2026: The IMS 2026 Debate

CME Congresses .

September 26th- Live from IMS 2026: The IMS 2026 Debate

September 25th- Live from IMS 2026: Plenary session of the 23rd Annual Meeting of the International Myeloma Society

CME Congresses .

September 25th- Live from IMS 2026: Plenary session of the 23rd Annual Meeting of the International Myeloma Society

September 24th- Live from IMS 2026: Can the gut microbiome influence the efficacy and toxicity of CAR-T cells — and could we eventually manipulate it to improve patient outcomes?

CME Congresses .

September 24th- Live from IMS 2026: Can the gut microbiome influence the efficacy and toxicity of CAR-T cells — and could we eventually manipulate it to improve patient outcomes?

September 23rd- Live from IMS 2026: T-cell Engagers to Reorganize the Cytotoxic Immunological Synapse

CME Congresses .

September 23rd- Live from IMS 2026: T-cell Engagers to Reorganize the Cytotoxic Immunological Synapse

September 23rd- Live from IMS 2026: Rethinking First Relapse in Multiple Myeloma: CAR-T, Bispecifics, ADCs and the Challenge of Sequencing

CME Congresses .

September 23rd- Live from IMS 2026: Rethinking First Relapse in Multiple Myeloma: CAR-T, Bispecifics, ADCs and the Challenge of Sequencing

September 22nd- MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

CME Congresses .

September 22nd- MaaT013 fecal microbiotherapy modulates key gastro-intestinal and immunological processes involved in GvHD pathogenesis in vitro and in vivo

September 21st- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

CME Congresses .

September 21st- FcRH5×CD3 bispecific antibody cevostamab in relapsed or refractory multiple myeloma: a phase 1 trial

September 15th- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

CME Congresses .

September 15th- Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study

September 9th- Can three complementary mechanisms transform the treatment of one of the rarest and most aggressive hematologic malignancies?

CME Congresses .

September 9th- Can three complementary mechanisms transform the treatment of one of the rarest and most aggressive hematologic malignancies?